Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 Jun. 29 at 8:13 PM

$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:54 PM

$SLS $GILD $ABBV What's really F'd Up Here - is the real investors who've loaded in here - Know - SLS Could Announce a Sale of SLS009 - the Secondary Asset - for $7B and noone would blink an eye. - just the secondary asset, SLS009 is worth at least $5 to $7B - $25 -$30 per share, right now. SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B...

0 · Reply

BarbaraSmith247 Jun. 29 at 7:50 PM

$ABBV trading around 255.30 today. Seeing some action on the pipeline front with trial milestones and regulatory opinions, which is keeping the sentiment constructive. Still, not looking to force a trade at these levels. Patience is the play.

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:40 PM

$SLS $ABBV $SLS https://pmc.ncbi.nlm.nih.gov/articles/PMC10123586/#Sec7 iykyk / 80th EVENT PR is now Imminent.

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:33 PM

$SLS $ABBV Share Price will Continue climbing until it Absolutely Launches. -- BAT FAILED 4 Recent AML Trials, Dr's Treating Actual SLS P3 Patients are on Record Stating BAT is Toxic, MOS is Dismal, extremely poor and they 'strongly believe Gps will reach the primary endpoint" - and 'revolutionize AML Remission maintenance'. Most who know are fairly Sure GPs is Golden, (if you don't know) The only real question is - What is Gps Worth? Cco Published Minimum Estimated Pricing $280K Rev P/p Y1 12,500 AML CR2 Patients Each Year 40,000 AML CR1 Patients Each Year +100,000 AML Patients Currently in Remission Who'll Immediately Benefit from GPs - right out of the GATE - Compounded Revenue / Infinite Dosing / - WT1 97% of ALL AML Patients.

0 · Reply

PeterRaslow Jun. 29 at 7:00 PM

$SLS with $ABBV not releasing the maintenance data for Viola studies this is my biggest Green Flag for a win take that to the bank

1 · Reply

WallStreetBulll Jun. 29 at 6:36 PM

Market sentiment for $ABBV is bullish, with the stock trading at $255.40. Investors are noting a 9-month base breakout, suggesting potential for sustained momentum.

0 · Reply

liamsniperalert Jun. 29 at 4:31 PM

$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.75 772% GAINER! 🏆🗻

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 3:42 PM

$SLS $ABBV Does Every One know - Aza+VEN, BAT - Best Available Treatment for SLS P3 Control Arm Patients Recently Failed 4 large AML Trials conducted by ABBV? - Including FAILING 3 For AML Remission Maintenance? VIALE-M Phase 3 Trial for CR1 Maintenance FAILED VIALE-T Phase 3 Trial For post Transplant Maintenance Failed Large Phase 2 Reduced Intensity all Oral Failed Verona Phase 3 HR MDS/AML Precursor Failed -- AND -- We have 3 Dr's treating Actual SLS Phase 3 Patients on the Record Stating BAT is Toxic, MOS is 'Not Durable', 'Extremely poor", 'just 6-8 months 5-7 months' ---AND " I strongly believe Gps will reach the primary Endpoint "... It is not Complicated.

0 · Reply

Blockwave1 Jun. 29 at 2:59 PM

$ABBV MUCH LOVE❤️

0 · Reply

AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

GMAB

$AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Jun 29, 2026, 4:15 PM EDT - 2 hours ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2026-06-29T09:20:22.000Z - 13 hours ago

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

Jun 29, 2026, 3:10 AM EDT - 15 hours ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:00 AM EDT - 15 hours ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

2026-06-26T20:55:10.000Z - 3 days ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

Jun 26, 2026, 4:50 PM EDT - 3 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 2:39 PM EDT - 3 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 3 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 24, 2026, 12:51 PM EDT - 5 days ago

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 5 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

2026-06-23T12:54:44.000Z - 6 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:22:00.000Z - 6 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Jun 23, 2026, 8:00 AM EDT - 6 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

2026-06-23T11:29:50.000Z - 6 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

2026-06-23T11:04:51.000Z - 6 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

2026-06-23T10:24:35.000Z - 6 days ago

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:00:54.000Z - 6 days ago

AbbVie announces European Commission approval of Maviret

2026-06-23T09:46:03.000Z - 6 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

Jun 23, 2026, 5:00 AM EDT - 6 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 6 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

2026-06-22T21:55:09.000Z - 7 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Jun 22, 2026, 10:30 AM EDT - 7 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Press release: M&A announcement

2026-06-22T12:24:03.000Z - 7 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

Jun 22, 2026, 7:42 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

2026-06-22T11:15:52.000Z - 7 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

Jun 22, 2026, 7:06 AM EDT - 7 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 7 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 7 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Jun 20, 2026, 12:11 PM EDT - 9 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 10 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 11 days ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 13 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 17 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 11, 2026, 7:14 AM EDT - 18 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

Jun 10, 2026, 11:47 AM EDT - 19 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 20 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 21 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 25 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 26 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 27 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

55X_ROI_Q1_2026 Jun. 29 at 8:13 PM

$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:54 PM

0 · Reply

BarbaraSmith247 Jun. 29 at 7:50 PM

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:40 PM

$SLS $ABBV $SLS https://pmc.ncbi.nlm.nih.gov/articles/PMC10123586/#Sec7 iykyk / 80th EVENT PR is now Imminent.

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 7:33 PM

0 · Reply

PeterRaslow Jun. 29 at 7:00 PM

$SLS with $ABBV not releasing the maintenance data for Viola studies this is my biggest Green Flag for a win take that to the bank

1 · Reply

WallStreetBulll Jun. 29 at 6:36 PM

Market sentiment for $ABBV is bullish, with the stock trading at $255.40. Investors are noting a 9-month base breakout, suggesting potential for sustained momentum.

0 · Reply

liamsniperalert Jun. 29 at 4:31 PM

$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.75 772% GAINER! 🏆🗻

0 · Reply

55X_ROI_Q1_2026 Jun. 29 at 3:42 PM

0 · Reply

Blockwave1 Jun. 29 at 2:59 PM

$ABBV MUCH LOVE❤️

0 · Reply

Blockwave1 Jun. 29 at 2:57 PM

$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 🤑 667% GAINER! ☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️

0 · Reply

StockpeakHQ_1 Jun. 29 at 2:56 PM

$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 667% GAINER!

0 · Reply

Blockwave1 Jun. 29 at 2:35 PM

Telegram channel: https://t.me/BlockWave10 $ABBV You can call me the GOAT if you want. 😂🫶🏻 Heaven knows I’ll keep doing my part. Keep missing these opportunities, and you’ll keep missing out on making some serious profit.

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM

$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM

$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹

0 · Reply

Snipertradesexpert Jun. 29 at 2:06 PM

$ABBV Take a look🥂

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:01 PM

$ABBV $PFE $RVMD $SLS 🤩 Over 6.4 million Volume in first half hour up over 15%. I expect a T 1 halt before the Biggest Catalyst in Sellas Corporate history GPS Regal Pivotal Registrational phase 3 data= $120.00+ BO= $240.00+ Bidding War= $280.00+ ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 1:49 PM

$ABBV $PFE $RVMD $SLS Potential T1 halt before next Catalyst. Traders and Repositioners will be left on the sidelines! SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹

0 · Reply

ApexEquityVault Jun. 29 at 1:40 PM

OH MY GOD!!!!!! I JUST MADE $19,000+ ON $ABBV I DO NOT MISS (NFA)

0 · Reply

Blockwave1 Jun. 29 at 1:37 PM

I JUST MADE $19,000+ ON $ABBV I DO NOT MISS ON MY HIGH CONFIDENCES!!!!!!

0 · Reply

StockpeakHQ_1 Jun. 29 at 1:36 PM

$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $2.50 481% GAINER!

0 · Reply

Snipertradesexpert Jun. 29 at 1:36 PM

$1.00 on $ABBV here! 47% return!

0 · Reply

Market Cap	447.62B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	24.86
Forward PE	17.03
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	9,758,976
Avg Vol	7,227,618
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	100%
Beta	0.32
Analysts	Strong Sell
Price Target	$250.97